ViiV Healthcare presents GEMINI 1 & 2 studies through Week 96 showing 2-drug regimen of dolutegravir plus lamivudine continues to demonstrate high efficacy rates and no cases of treatment emergent resistance

This is an archived press release which may not reflect current medical knowledge and should not be used as a source of information on the present label, safety data or efficacy data for ViiV Healthcare products and/or their uses. Please refer to your nationally approved label or summary of product characteristics for up-to-date product information.